Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2006-08-29
2006-08-29
Swartz, Rodney P (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S241100, C424S275100, C424S282100, C424S810000, C514S885000, C530S868000
Reexamination Certificate
active
07097845
ABSTRACT:
This invention provides combinations of a tolerance-inducing antigen such as insulin and a mucosal binding component that preferably binds ganglioside GM1. The components are present in a non-covalent arrangement. When administered to a mucosal surface, the combinations are effective in inducing specific immunological tolerance at a 10-fold lower dose than antigen alone. Tolerance is sustained for a number of weeks without the necessity of booster administrations. The compositions and procedures of this invention are of benefit for the prevention or amelioration of conditions attributable to an unwanted immunological response.
REFERENCES:
patent: 4666837 (1987-05-01), Harford et al.
patent: 5399347 (1995-03-01), Trentham et al.
patent: 5681571 (1997-10-01), Holmgren et al.
patent: 0 474 453 (1992-03-01), None
patent: 666 080 (1995-08-01), None
patent: 2-235823 (1990-09-01), None
patent: 3-109328 (1991-05-01), None
patent: WO 91/08760 (1991-06-01), None
patent: WO 91/12816 (1991-09-01), None
patent: WO 92/07581 (1992-05-01), None
patent: WO 93/16724 (1993-09-01), None
patent: WO 94/07516 (1994-04-01), None
patent: WO 94/27634 (1994-12-01), None
patent: WO 95/10301 (1995-04-01), None
patent: WO 96/17620 (1996-06-01), None
patent: WO 96/21458 (1996-07-01), None
patent: WO 96/39176 (1996-12-01), None
Elson, Charles O. et al. (1984). “Generalized Systemic and Mucosal Immuniry in Mice after Mucosal stimulation with Cholera Toxin,” Chemical Immunology 132(6): 2736-2741.
Liu, L.M. et al. (1998). “T-Cell Response to Orally Administered Antigens and Its Role in the Treatment of Autoimmune Diseases,” Chemical Immunology 71: 139-160.
McKenzie, Sara J. et al. (1984). “Cholera Toxin B Subunit as a Carrier Protein to Stimulate a Mucosal Immune Response,” 153(4): 1818-1824.
Strobel, Stephan et al. (1998). “Immune Responses to Dietary Antigens: Oral Tolerance,” 19(4).
Yankelevich, B. et al., “Prevention of Acute Graft-Versus-Host Disease by Treatment with a Novel Immunosuppressant”J. Immunol. 154:3611-3617 (1995).
Chen et al., “Regulatory T cell clones induced by oral tolerance: Suppresion of autoimmune encephalomyelitis”Science 265:1237-1240 (1994).
Elson, “Cholera toxin and its subunits as potential oral adjuvants”Curr. Top. Microbial. Immunol. 146:29-33 (1989).
Frey et al., “Role of the glycocalyx in regualting access of microparticles to apical plasma membranes of intestinal epithelial cells: Implications for microbial attachment and oral vaccine targeting”J. Exp. Med. 184:1045-1059 (1996).
McKenzie et al., “Cholera toxin B subunit as a carrier protein to stimulate a mucosal immune response”J. Immunol. 139:1818-1824 (1984).
Nedrud et al., “combined oral
asal immunization protects mice from sedai virus infection”J. Immunol. 139:3484-3492 (1987).
Sun et al., “Cholera Toxin B subunit: An efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance”Proc. Natl. Acad. Sci. USA 91:10795-10799 (1994).
Sun et al., “Treatmnet of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit”Proc. Natl. Acad. Sci. USA 93:7196-7201 (1996).
Thompson et al., “suppression of collagen induced arthritis by oral administration of type II collagen: Changes in immune and arthritic responses mediated by active peripheral suppression”Autoimmunity 16:189-199 (1993).
Wang et al., “T cell reactivity to acetylcholine receptor in rats orally tolerized against experimental autoimmune myastheina gravis”Cell Immunol. 152:394-404 (1993).
Weiner et al., “Oral tolerance: Immune mechanisms and treatment of autoimmune diseases”Immunology Today 18:335-343 (1997).
Whitacre et al., “Oral tolerance in experimental autoimmune encephalomyelitis III. Evidence for clonal anergy”J. Immunol. 147:2155-2163 (1991).
Zhang et al., “Suppression of diabetes in nonobese diaetic mice ty odminstration of porcine insulin”Proc. Natl. Acad. Sci. USA 88:10252-10256 (1991).
Morrison & Foerster / LLP
Petersen Jacob Sten
Swartz Rodney P
LandOfFree
Combinations of antigen and mucosal binding component for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combinations of antigen and mucosal binding component for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combinations of antigen and mucosal binding component for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3670495